Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study
Background With the first and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), clinical benefit and rash correlate together. EGFR TKI-induced rash can be alleviated with tetracyclines, but it is unknown whether the use of tetracyclines can increase the sur...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-10-01
|
| Series: | ESMO Open |
| Online Access: | https://esmoopen.bmj.com/content/5/5/e000864.full |